title: [Case of multiple lung metastases of renal cell carcinoma failing to respond to Interferon-alpha (IFN-alpha) and sunitinib but markedly responding to everolimus].
abstract: The case pertains to a 47-year-old male. He consulted our institute regarding a tumor in his right kidney. Endoscopic retroperitoneal nephrectomy of the right kidney was conducted to remove the tumor. The postoperative pathology was Renal Cell Carcinoma (Clear cell carcinoma, pT1b, pNx, V (+), Fuhrman grade 4). Multiple lung metastases were observed upon CT scan the following year. Sunitinib was administered following Interferon alpha (IFN-alpha) therapy; however, the lung metastases became larger, so administration of everolimus at 10 mg/day was commenced. The lung metastatic lesion became smaller upon CT scan from 6 weeks following administration, and it was determined that the therapeutic effect was PR. The PR was still maintained upon CT scan 31 weeks following administration but the lung metastatic lesion still remained; therefore, right lower lobe resection and lymph node biopsy were conducted upon obtaining informed consent. The administration of everolimus at 10 mg/day is still subsequently being continued due to viable tumor cells being observed in the lung metastatic lesion and the lymph node. At present, 43 weeks have past since the start of everolimus administration, but no new metastatic lesions have been observed.
authors.affiliation: Department of Urology, Nagoya Daini Red Cross Hospital.
authors.forename: Toshinori
authors.initials: T
authors.lastname: Nishikimi
authors.forename: Toyonori
authors.initials: T
authors.lastname: Tsuzuki
authors.forename: Yushi
authors.initials: Y
authors.lastname: Yamauchi
authors.forename: Shinri
authors.initials: S
authors.lastname: Yoshida
authors.forename: Ryo
authors.initials: R
authors.lastname: Ishida
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamada
authors.forename: Keisuke
authors.initials: K
authors.lastname: Yokoi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kobayashi
mesh_terms: D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D004724:Endoscopy; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007211:Indoles; D016898:Interferon-alpha; D007680:Kidney Neoplasms / Q000473:pathology* / Q000601:surgery; D008175:Lung Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011013:Pneumonectomy; D011758:Pyrroles; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D007211:Indoles; D016898:Interferon-alpha; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus